Page 100 - Read Online

Kouroumalis et al. Hepatoma Res 2018;4:34 I http://dx.doi.org/10.20517/2394-5079.2018.33 Page 17 of 18

108. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with
octreotide: a randomised controlled study. Gut 1998;42:442-7.
109. Samonakis DN, Moschandreas J, Arnaoutis T, Skordilis P, Leontidis C, Vafiades I, Kouroumalis E. Treatment of hepatocellular
carcinoma with long acting somatostatin analogues. Oncol Rep 2002;9:903-7.
110. Patsanas T, Kapetanos D, Ilias A, Gessiou Ch, Tzarou V, Kokozidis G, Kitis G. Octreotide in the treatment of inoperable hepatocellular
carcinoma. Ann Gastroenterol 2004;17:69-74.
111. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou
C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepatocellular cancer and
overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 2007;13:3164-70.
112. Pan DY, Qiao JG, Chen JW, Huo YC, Zhou YK, Shi HA. Tamoxifen combined with octreotide or regular chemotherapeutic agents in
treatment of primary liver cancer: a randomized controlled trial. Hepatobiliary Pancreat Dis Int 2003;2:211-5.
113. Gill ML, Atiq M, Sattar S, Khokhar N. Treatment outcomes with long acting octreotide in inoperable hepatocellular carcinoma: a local
experience and review of literature. J Pak Med Assoc 2005;55:135-8.
114. Shah U, O’Neil B, Allen J, Goldberg RM, Bernard S, Moore D, Venook AP, Morse MM. A phase II study of long-acting octreotide in
patients with advanced hepatocellular carcinoma and CLIP score of 3 or higher. Gastrointest Cancer Res 2009;3:45-8.
115. Schöniger-Hekele M, Kettenbach J, Peck-Radosavljevic M, Müller C. Octreotide treatment of patients with hepatocellular carcinoma--a
retrospective single centre controlled study. J Exp Clin Cancer Res 2009;28:142.
116. Raderer M, Hejna MH, Kurtaran A, Kornek GV, Valencak JB, Oberhuber G, Vorbeck F, Virgolini I, Scheithauer W. Successful treatment
of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide. Am J Gastroenterol 1999;94:278-9.
117. Siveke J, Folwaczny C, Herberhold C. Complete regression of advanced HCC with long acting octreotide. Gut 2003;52:1531.
118. Borbath I, Lhommel R, Guiot Y, Coche E, Sempoux C. Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial
regression and more than 3 years of progression-free survival. Acta Gastroenterologica Belgica 2012;75:270-3.
119. Treiber G, Wex T, Rocken C, Fostitsch P, Malfertheiner P. Impact of biomarkers on disease survival and progression in patients treated
with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:699-708.
120. Li S, Liu Y, Shen Z. Characterization of somatostatin receptor 2 and 5 expression in operable hepatocellular carcinomas.
Hepatogastroenterology 2012;59:2054-8.
121. Liu Y, Jiang L, Mu Y. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related
hepatocellular carcinoma following octreotide long-acting release treatment. Oncology Lett 2013;6:821-8.
122. Plentz RR, Tillmann HL, Kubicka S, Bleck JS, Gebel M, Manns MP, Rudolph KL. Hepatocellular carcinoma and octreotide: treatment
results in prospectively assigned patients with advanced tumor and cirrhosis stage. J Gastroenterol Hepatol 2005;20:1422-8.
123. Montella L, Addeo R, Caraglia M, Faiola V, Guarrasi R, Vincenzi B, Palmeri A, Capasso E, Nocera V, Tarantino L, Ariete M, Martorelli A,
Del Prete S. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency
ablation plus octreotide: a single center experience. Oncol Rep 2008;20:385-90.
124. Jia W, Feng K, Fan P, Fan G, Yang S, Zhang T, Wei Q, Qian L. Post-TACE combination therapy of heparin and octreotide results in
decreased tumor metastasis in extrahepatic tumorigenesis. Cell Biochem Biophys 2012;62:35-40.
125. Tong H, Wei B, Chen S, Xie YM, Zhang MG, Zhang LH, Huang ZH, Tang CW. Adjuvant celecoxib and lanreotide following
transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget 2017;8:48303-12.
126. Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri
G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D’Agostino A, Faiola V, Addeo R. Sorafenib
plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR study. Cancer
Chemother Pharmacol 2010;66:837-44.
127. Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio B, Del Prete S, Abbruzzese
A, Stiuso P. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with
sorafenib plus octreotide LAR. Cell Death Dis 2011;2:e150.
128. Rabe C, Pilz T, Allgaier HP, Halm U, Strasser C, Wettstein M, Sauerbruch T, Caselmann WH. Clinical outcome of a cohort of 63
patients with hepatocellular carcinoma treated with octreotide. Z Gastroenterol 2002;40:395-400.
129. Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC. A randomized placebo-controlled study of long-acting
octreotide for treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-91.
130. Kouroumalis E, Samonakis D, Sordilis P. Octreotide treatment of hepatocellular carcinoma. Hepatology 2003;37:477.
131. Slijkhuis WA, Stadheim L, Hassoun ZM, Nzeako UC, Kremers WK, Talwalkar JA, Gores GJ. Octreotide therapy for advanced
hepatocellular carcinoma. J Clin Gastroenterol 2005;39:333-8.
132. Samonakis DN, Christodoulakis N, Kouroumalis EA. Octreotide for unresectable hepatocellular carcinoma: beyond the first sight. J
Clin Gastroenterol 2006;40:86-7.
133. Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, Garas G, Dowling A,
Crawford D, Ring J, Basser R, Strickland A, Macdonald G, Green M, Nowak A, Dickman B, Dhillon H, Gebski V; Australasian Gastro-
intestinal Trials group (AGITG) and Ag0001H Investigators. Somatostatin receptor expression, tumour response, and quality of life in
patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 2006;95:853-61.
134. Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis Van Laethem
JL. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a
randomised multicentre phase III study. Br J Cancer 2007;97:582-8.